Jim Davis

Yeah.

First, Katie, thanks for having us on this morning.

You know, in terms of the growth drivers, we really think there's two or three major things going on.

One, unfortunately, is still all of the chronic care disease management that's occurring in the country.

You know, type two diabetes at an all time high autoimmune disorders.

cancer rates, younger and younger patients being diagnosed with cancer, colon cancer in particular.

So all of this is leading to a lot of testing, as you can imagine, and helping people diagnose, helping people figure out what the right therapy they should select, and then actually monitoring the disease.

Now, at the other end of the spectrum, and this is really a more recent phenomenon, is all the new testing from a consumer health standpoint.

So, you know, prevention is all about doing something before the symptoms set in.

And between our own consumer health offering and then partnerships that we've developed in the industry, we are really powering the wellness industry today.

So our relationships with Function Health, our relationships with Whoop, with Aura,

We're trying to make lab testing ubiquitous to consumers, especially those that really have a focus on prevention and wellness.

But really, it's those two things, Katie, that are really driving the growth.

Yeah, so to put all of that in context between our own direct business, our own consumer direct business, plus our partnerships with all those that you mentioned, it's about a $250 million segment.

And, you know, we did $11 billion last year.

So it's meaningful.

What's more meaningful is that segment grew at over 30% last year, and we expect it to continue to grow, you know, north of 20% this year.

And again, what we're seeing is just consumers taking more interest in their health with this notion of let's prevent disease.

Let's try to get in front of that.

You know, if we look at our business today, about two-thirds of it is diagnosis of disease, you know, treatment of disease, treatment monitoring.